Robert Getzenberg

Company: Astellas Pharmaceuticals

Job title: Medical Director, Diagnostics, Oncology

Seminars:

Claudin18.2 Identifies a Previously Undefined Patient Population with Gastric/GEJ Cancer 11:30 am

Claudin 18.2 is a tight junction protein that during transformation is retained and exposed for detection Claudin 18.2 can be detected by IHC and is prevalent in a significant percentage of patients  The biomarker Claudin 18.2 may guide treatment decisions in these patientsRead more

day: Day 2 Track B AM